Galectins testing: New promises for the diagnosis and risk stratification of chronic diseases?

Clinical Biochemistry

Volumn 45, Issue 10-11, 2012, Pages 719-726

  Gruson, Damien ^a   Ko, Gabriel ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b GKo and co consulting   (France)

Author keywords

Biomarker; Cancer; Colorectal; Galectin; Heart failure; Thyroid

Indexed keywords

GALECTIN; GALECTIN 3;

ATHEROSCLEROSIS; BREAST CANCER; CANCER DIAGNOSIS; CARDIOVASCULAR DISEASE; CELL GROWTH; CELL VIABILITY; CHRONIC DISEASE; COLORECTAL CANCER; DIABETES MELLITUS; DISEASE MARKER; GENE EXPRESSION REGULATION; HEAD AND NECK CANCER; HEART FAILURE; HUMAN; IMMUNE RESPONSE; NEOPLASM; PATHOPHYSIOLOGY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; THYROID CANCER;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; GALECTIN 1; GALECTIN 3; GALECTINS; HUMANS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 84862578799     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.04.009     Document Type: Review

References (100)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
2. Adams L., Scott G.K., Weinberg C.S. Biphasic modulation of cell growth by recombinant human galectin-1. Biochim Biophys Acta 1996, 1312:137-144.
3. Al-Ansari S., Zeebregts C.J., Slart R.H., Peppelenbosch M., Tio R.A. Galectins in atherosclerotic disease. Trends Cardiovasc Med 2009, 19:164-169.
4. Balat O., Aksoy F., Kutlar I., Ugur M.G., Iyikosker H., Balat A., Anarat R., et al. Increased plasma levels of urotensin-II in preeclampsia-eclampsia: a new mediator in pathogenesis?. Eur J Obstet Gynecol Reprod Biol 2005, 120:33-38.
5. Barondes S.H., Castronovo V., Cooper D.N., Cummings R.D., Drickamer K., Feizi T., et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994, 76:597-598.
6. Barondes S.H., Cooper D.N., Gitt M.A., Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994, 19(269):20807-20810.
7. Barrow H., Guo X., Wandall H.H., Pedersen J.W., Fu B., Zhao Q., et al. Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res 2011, 17:7035-7046.
8. Barrow H., Rhodes J.M., Yu L.G. The role of galectins in colorectal cancer progression. Int J Cancer 2011, 129:1-8.
9. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358:2148-2159.
10. Bresalier R.S., Mazurek N., Sternberg L.R., Byrd J.C., Yunker CK., Nangia-Makker P., et al. Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3. Gastroenterology 1998, 115:287-296.
11. Camby I., Le M.M., Lefranc F., Kiss R. Galectin-1: a small protein with major functions. Glycobiology 2006, 16:137R-157R.
12. Carlsson M.C., Balog C.I., Kilsgård O., Hellmark T., Bakoush O., Segelmark M., et al. Different fractions of human serum glycoproteins bind galectin-1 or galectin-8, and their ratio may provide a refined biomarker for pathophysiological conditions in cancer and inflammatory disease. Biochim Biophys Acta 2012 Jan 17, [Epub ahead of print].
13. Carlsson M.C., Cederfur C., Schaar V., Balog C.I., Lepur A., Touret F., et al. Galectin-1-binding glycoforms of haptoglobin with altered intracellular trafficking, and increase in metastatic breast cancer patients. PLoS One 2011, 6:e26560.
14. Chiu C.G., Strugnell S.S., Griffith O.L., Jones S.J., Gown A.M., Walker B., et al. Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010, 176:2067-2081.
15. Christenson R.H. Preamble: National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for utilization of biomarkers in acute coronary syndromes and heart failure. Clin Biochem 2008, 41:208-209.
16. Christenson R.H., Duh S.H., Wu A.H., Smith A., Abel G., deFilippi C.R., et al. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin Biochem 2010, 43:683-690.
17. Clerico A., Vittorini S., Passino C., Emdin M. New and emerging biomarkers of heart failure. Crit Rev Clin Lab Sci 2009, 46:107-128.
18. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000, 35:569-582.
19. Cooper D.N., Barondes S.H. God must love galectins; he made so many of them. Glycobiology 1999, 9:979-984.
20. Cooper M.E., Bonnet F., Oldfield M., Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens 2001, 14:475-486.
21. Cooper M.E., Johnston C.I. Optimizing treatment of hypertension in patients with diabetes. JAMA 2000, 283:3177-3179.
22. Dagher S.F., Wang J.L., Patterson R.J. Identification of galectin-3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci U S A 1995, 92:1213-1217.
23. Dancer J.Y., Truong L.D., Zhai Q., Shen S.S. Expression of Galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker. Arch Pathol Lab Med 2010, 134:90-94.
24. de Boer R.A., van Veldhuisen D.J., Gansevoort R.T., Muller Kobold A.C., van Gilst W.H., Hillege H.L., et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2011, 10-2796.
25. de Boer R.A., Voors A.A., Muntendam P., van Gilst W.H., van Veldhuisen D.J. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009, 11:811-817.
26. McCullough P.A., Olobatoke A., Vanhecke T.E. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med 2011, 12(4):200-210.
27. de Boer R.A., Yu L., van Veldhuisen D.J. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010, 7:1-8.
28. Demetter P., Nagy N., Martin B., Mathieu A., Dumont P., Decaestecker C., et al. The galectin family and digestive disease. J Pathol 2008, 215:1-12.
29. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson P.A., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29:2388-2442.
30. Dunlay S.M., Shah N.D., Shi Q., Morlan B., VanHouten H., Long K.H., et al. Lifetime costs of medical care after heart failure diagnosis. Circ Cardiovasc Qual Outcomes 2011, 4:68-75.
31. Elola M.T., Wolfenstein-Todel C., Troncoso M.F., Vasta G.R., Rabinovich G.A. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 2007, 64:1679-1700.
32. Gharib H., Papini E. Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am 2007, 36:707-735. vi.
33. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
34. Hernandez J.D., Baum L.G. Ah, sweet mystery of death! Galectins and control of cell fate. Glycobiology 2002, 12:127R-136R.
35. Hittelet A., Legendre H., Nagy N., Bronckart Y., Pector J.C., Salmon I., et al. Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer 2003, 103:370-379. %20.
36. Horiguchi N., Arimoto K., Mizutani A., Endo-Ichikawa Y., Nakada H., Taketani S. Galectin-1 induces cell adhesion to the extracellular matrix and apoptosis of non-adherent human colon cancer Colo201 cells. J Biochem 2003, 134:869-874.
37. Huflejt M.E., Leffler H. Galectin-4 in normal tissues and cancer. Glycoconj J 2004, 20:247-255.
38. Hughes R.C. The galectin family of mammalian carbohydrate-binding molecules. Biochem Soc Trans 1997, 25:1194-1198.
39. Hughes R.C. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta 1999, 1473:172-185.
40. Inohara H., Segawa T., Miyauchi A., Yoshii T., Nakahara S., Raz A., et al. Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Biochem Biophys Res Commun 2008, 376:605-610.
41. Išić T., Savin S., Cvejić D., Marečko I., Tatić S., Havelka M., et al. Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors. J Cancer Res Clin Oncol 2010, 136:1805-1812.
42. Jaffe A.S., Babuin L., Apple F.S. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006, 48:1-11.
43. Karlsson A., Follin P., Leffler H., Dahlgren C. Galectin-3 activates the NADPH-oxidase in exudated but not peripheral blood neutrophils. Blood 1998, 91:3430-3438.
44. Kim H.R., Lin H.M., Biliran H., Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 1999, 59:4148-4154.
45. Leffler H., Carlsson S., Hedlund M., Qian Y., Poirier F. Introduction to galectins. Glycoconj J 2004, 19:433-440.
46. Levine R.J., Lam C., Qian C., Yu K.F., Maynard S.E., Sachs B.P., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006, 355:992-1005.
47. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672-683.
48. Lin Y.H., Lin L.Y., Wu Y.W., Chien K.L., Lee C.M., Hsu R.B., et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009, 409:96-99.
49. Liu F.T., Hsu D.K., Zuberi R.I., Kuwabara I., Chi E.Y., Henderson W.R. Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. Am J Pathol 1995, 147:1016-1028.
50. Liu F.T., Rabinovich G.A. Galectins as modulators of tumour progression. Nat Rev Cancer 2005, 5:29-41.
51. Liu X., Feng Q., Chen Y., Zuo J., Gupta N., Chang Y., et al. Proteomics-based identification of differentially-expressed proteins including galectin-1 in the blood plasma of type 2 diabetic patients. J Proteome Res 2009, 8:1255-1262.
52. Lok D.J., Van Der Meer P., de la Porte P.W., Lipsic E., Van Wijngaarden J., Hillege H.L., et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010, 99:323-328.
53. Lopez-Andrès N., Rossignol P., Iraqi W., Fay R., Nuée J., Ghio S., et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012, 14(1):74-81.
54. Meetoo D., McGovern P., Safadi R. An epidemiological overview of diabetes across the world. Br J Nurs 2007, 16:1002-1007.
55. Mensah-Brown E.P., Al Rabesi Z., Shahin A., Al Shamsi M., Arsenijevic N., Hsu D.K., et al. Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. Clin Immunol 2009, 130:83-88.
56. Moiseeva E.P., Williams B., Goodall A.H., Samani N.J. Galectin-1 interacts with beta-1 subunit of integrin. Biochem Biophys Res Commun 2003, 310:1010-1016.
57. Moiseeva E.P., Williams B., Samani N.J. Galectin 1 inhibits incorporation of vitronectin and chondroitin sulfate B into the extracellular matrix of human vascular smooth muscle cells. Biochim Biophys Acta 2003, 1619:125-132. %20.
58. Nagy N., Legendre H., Engels O., André S., Kaltner H., Wasano K., et al. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer 2003, 97:1849-1858.
59. Odegard R.A., Vatten L.J., Nilsen S.T., Salvesen K.A., Austgulen R. Preeclampsia and fetal growth. Obstet Gynecol 2000, 96:950-955.
60. Odibo A.O., Zhong Y., Goetzinger K.R., Odibo L., Bick J.L., Bower C.R., et al. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia. Placenta 2011, 32:598-602.
61. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992, 20:248-254.
62. Paron I., Scaloni A., Pines A., Bachi A., Liu F.T., Puppin C., et al. Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochem Biophys Res Commun 2003, 302:545-553.
63. Perillo N.L., Pace K.E., Seilhamer J.J., Baum L.G. Apoptosis of T cells mediated by galectin-1. Nature 1995, 378:736-739.
64. Perone M.J., Bertera S., Shufesky W.J., Divito S.J., Montecalvo A., Mathers A.R., et al. Suppression of autoimmune diabetes by soluble galectin-1. J Immunol 2009, 182:2641-2653.
65. Piano M.R., Prasun M. Neurohormone activation. Crit Care Nurs Clin North Am 2003, 15:413-421.
66. Puche A.C., Poirier F., Hair M., Bartlett P.F., Key B. Role of galectin-1 in the developing mouse olfactory system. Dev Biol 1996, 179:274-287.
67. Revkin J.H., Shear C.L., Pouleur H.G., Ryder S.W., Orloff D.G. Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future. Pharmacol Rev 2007, 59:40-53.
68. Roberts J.M., Cooper D.W. Pathogenesis and genetics of pre-eclampsia. Lancet 2001, 357:53-56.
69. Rosamond W., Flegal K., Friday G., Furie K., Go A., Greenlund K., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:e69-e171.
70. Sammar M., Nisemblat S., Fleischfarb Z., Golan A., Sadan O., Meiri H., et al. Placenta-bound and body fluid PP13 and its mRNA in normal pregnancy compared to preeclampsia, HELLP and preterm delivery. Placenta 2011, 32:S30-S36. Suppl.
71. Sano H., Hsu D.K., Yu L., Apgar J.R., Kuwabara I., Yamanaka T., et al. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 2000, 165:2156-2164.
72. Saussez S., Camby I., Toubeau G., Kiss R. Galectins as modulators of tumor progression in head and neck squamous cell carcinomas. Head Neck 2007, 29:874-884.
73. Saussez S., Decaestecker C., Mahillon V., Cludts S., Capouillez A., Chevalier D., et al. Galectin-3 upregulation during tumor progression in head and neck cancer. Laryngoscope 2008, 118:1583-1590.
74. Saussez S., Lorfevre F., Lequeux T., Laurent G., Chantrain G., Vertongen F., et al. The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol 2008, 44:86-93.
75. Schoeppner H.L., Raz A., Ho S.B., Bresalier R.S. Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 1995, 75:2818-2826.
76. Seetharaman J., Kanigsberg A., Slaaby R., Leffler H., Barondes SH., Rini J.M., et al. X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-A resolution. J Biol Chem 1998, 273:13047-13052.
77. Shah R.V., Chen-Tournoux A.A., Picard M.H., van Kimmenade R.R., Januzzi J.L. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010, 12:826-832.
78. Felker G.M., Fiuzat M., Shaw L.K., Clare R., Whellan D.J., Bettari L., et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012, 5(1):72-78.
79. Sharma U.C., Pokharel S., van Brakel T.J., van Berlo J.H., Cleutjens J.P., Schroen B., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110:3121-3128.
80. Shimura T., Takenaka Y., Fukumori T., Tsutsumi S., Okada K., Hogan V., et al. Implication of galectin-3 in Wnt signaling. Cancer Res 2005, 65:3535-3537.
81. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet 2005, 365:785-799.
82. Song S., Mazurek N., Liu C., Sun Y., Ding Q.Q., Liu K., et al. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res 2009, 69:1343-1349.
83. Stewart S., Jenkins A., Buchan S., McGuire A., Capewell S., McMurray J.J. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002, 4:361-371.
84. Stewart S., MacIntyre K., Hole D.J., Capewell S., McMurray J.J. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001, 3:315-322.
85. Takahashi K., Ghatei M.A., Lam H.C., O'Halloran D.J., Bloom S.R. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990, 33:306-310.
86. Takenaka Y., Inohara H., Yoshii T., Oshima K., Nakahara S., Akahani S., et al. Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett 2003, 195:111-119.
87. Tendera M. The epidemiology of heart failure. J Renin Angiotensin Aldosterone Syst 2004, 5(Suppl. 1):S2-S6.
88. Ueland T., Aukrust P., Broch K., Aakhus S., Skårdal R., Muntendam P., et al. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int J Cardiol 2011, 150:361-364.
89. van Kimmenade R.R., Januzzi J.L., Ellinor P.T., Sharma U.C., Bakker J.A., Low A.F., et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006, 19(48):1217-1224.
90. Vyakarnam A., Dagher S.F., Wang J.L., Patterson R.J. Evidence for a role for galectin-1 in pre-mRNA splicing. Mol Cell Biol 1997, 17:4730-4737.
91. Wada J., Kanwar Y.S. Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem 1997, 272:6078-6086.
92. Watanabe M., Takemasa I., Kaneko N., Yokoyama Y., Matsuo E., Iwasa S., et al. Clinical significance of circulating galectins as colorectal cancer markers. Oncol Rep 2011, 25:1217-1226.
93. Weber M., Sporrer D., Weigert J., Wanninger J., Neumeier M., Wurm S., et al. Adiponectin downregulates galectin-3 whose cellular form is elevated whereas its soluble form is reduced in type 2 diabetic monocytes. FEBS Lett 2009, 19(583):3718-3724.
94. Weigert J., Neumeier M., Wanninger J., Bauer S., Farkas S., Scherer M.N., et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 2010, 95:1404-1411.
95. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
96. Wild S.H., Forouhi N.G. What is the scale of the future diabetes epidemic, and how certain are we about it?. Diabetologia 2007, 50:903-905.
97. Wiseman S.M., Melck A., Masoudi H., Ghaidi F., Goldstein L., Gown A., et al. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol 2008, 15:2811-2826.
98. Yamaoka K., Ingendoh A., Tsubuki S., Nagai Y., Sanai Y. Structural and functional characterization of a novel tumor-derived rat galectin-1 having transforming growth factor (TGF) activity: the relationship between intramolecular disulfide bridges and TGF activity. J Biochem 1996, 119:878-886.
99. Zaia P.L., Oshima C.T., de Oliveira L.F., Andrade Scherholz P.L., Manoukian F.N. Immunoexpression of galectin-3 in colorectal cancer and its relationship with survival. J Gastrointest Cancer 2011, 42:217-221.
100. Zaninotto M., Mion M.M., Novello E., Altinier S., Plebani M. New biochemical markers: from bench to bedside. Clin Chim Acta 2007, 381:14-20.